We have compared Duffy blood group genotype distribution, as determined by polymerase chain reaction with allele-specific primers, in 68 Plasmodium vivax-infected patients and 59 non-vivax malaria controls from Rondônia, Brazil. Homozygosity for the allele Fy, which abolishes Duffy antigen expression on erythrocytes, was observed in 12% non-vivax controls but in no P. vivax patient. However, no significant association was found between Fy heterozygosity and protection against P. vivax. The Fy x allele, which has recently been associated with very weak erythrocyte expression of Duffy antigen, was not found in local P. vivax patients. Key-words: Plasmodium vivax. Malaria. Duffy antigen. Genotypes. Brazilian Amazon.
The incidence of malaria in Brazil has increased dramatically in recent decades, from 52,000 cases recorded in 1970 to more than 630,000 cases in 1999. A major change has also been observed in the distribution of Plasmodium species over the last years: in the 1980s, P. falciparum and P. vivax were similarly prevalent, while in 1999 P. vivax was detected in more than 80% of malaria cases diagnosed microscopically in Brazil. P. malariae has been officially reported in less than 0.5% of malaria patients in the 1990s (National Health Foundation, unpublished data). Malaria transmission in Brazil occurs essentially in the Amazon Basin, where more than 99% of infections are acquired. Most affected subjects are migrants living in frontier agricultural settlements and mining areas 8 .
Little is known on the frequency of erythroid polymorphisms that confer either partial or complete resistance against malaria, such as sickle cell anaemia trait, α + -thalassemia and Duffy blood group negativity 9 , in Amazonian populations. Duffy blood group polymorphisms are important in areas where P. vivax predominates, because this molecule acts as a receptor for P. vivax (but not for the other human malaria parasites) on the surface of red blood cells (RBCs) 9 . The Duffy antigen (Fy) is also normally expressed in endothelial cells of kidney collecting ducts and pulmonary alveoli, and in Purkinje cells of the cerebellum; its physiologic function is unknown, but Fy is thought to serve as a scavenger for circulating chemokines 13 . 12 15 , and (b) the G298A mutation, frequently found in either Fy a or Fy b -type sequences, which seems to be physiologically silent (Figure 1 ) 13 . The combination of these polymorphisms leads to the major Duffy phenotypes Fy (a+b+), Fy(a+b-), Fy(a-b+), Fy(a-b-) and Fy(a-b+ WK ) (WK stands for weak) 13 . , and arrows indicate the location and orientation of the allele-specific oligonucleotide primers (FYAB2, GATAFY2, FYAREV, FYBREV) used for genotyping 11 and the FY3 and FY4 primers used for amplifying a 661-bp fragment for sequence analysis 12 . Primer sequences (from 5´ to 3´) are as follows: FYAB2, CTC ATT AGT CCT TGG CTC TTA T; GATAFY2, CTC ATT AGT CCT TGG CTC TTA C; FYAREV, AGC TGC TTC CAG GTT GGC AC; FYBREV, AGC TGC TTC CAG GTT GGC AT (note that these two pairs of forward and reverse allele-specific primers differ in a single nucleotide [T or C] at the 3´end); FY3, CCC TCT TGT GTC CCT CCC TTT, and FY4, CAG AGC TGC GAG TGC TAC CTA. The nucleotide replacements C265T and G298A in exon 2, marked with asterisks, may be detected by restriction fragment length polymorphism analysis using the restriction enzymes AciI and MwoI, respectively 12 .
RBCs from individuals presenting the Duffy phenotypes Fy(a+b+), Fy(a+b-) and Fy(a-b+) are similarly susceptible to P. vivax invasion, while those with the Fy(a-b-) phenotype are fully refractory to this parasite. Patients with non-vivax malaria served as sympatric malaria-exposed controls. Since P. falciparum, P. vivax and P. malariae co-circulate in the same areas in Rondônia, patients infected with other malaria parasites are similarly exposed to P. vivax. If GATA-1 mutation heterozygosity confers some protection against P. vivax, due to a decreased erythrocyte Fy antigen expression, a relative excess of wild-type homozygotes among P. vivax-infected patients, as compared with non-vivax controls, would be expected 17 . Venous blood was collected, after informed consent, from 127 patients with microscopically confirmed malaria diagnosis. No attempt was made to classify donors according to ethnic groups, but Amerindians were not included in the study sample. Human DNA was isolated using standard phenol-chloroform extraction and ethanol precipitation protocols 3 . On-site Plasmodium species identification was made by standard thick smear microscopy 4 , and further confirmed by species-specific polymerase chain reaction (PCR) (in 97 [76%] patients) or by reexamination of available blood smears by one of the authors (in 30 [24%] patients). The semi-nested PCR used for species identification 6 was performed exactly as described elsewhere 1 . All patients had a febrile illness and were clinically examined by one of the authors at outpatient malaria clinics in Porto Velho, Rondônia, between 1995 and 1998. Antimalarial treatment was given, following the recommendations of the National Health Foundation 4 , based on on-site species identification.
Duffy blood group genotyping was performed essentially as described by Olsson and colleagues 11 . Amplification was performed with the forward oligonucleotide primers GATAFY2 (that targets the mutated GATA-1 promoter sequence) and FYAB2 (that targets the wild-type promoter sequence), and the forward primers FYAREV (that targets the Fy a ORF allele) and FYBREV2 (that targets the Fy b ORF allele). Oligonucleotide primer locations, orientations and sequences are given in Figure 1 11 . Four separate reactions were prepared for each patient, using the following primer combinations: GATAFY2 and FYAREV, GATAFY2 and FYBREV2, FYAB2 and FYAREV, and The first group included all patients harbouring P. vivax (n = 68), regardless of the presence of a second malaria species; the second group included all patients harbouring malaria species other than P. vivax (n = 59). b wt = wild-type; m = mutated (i. e., presenting the T-33C substitution).
c ISBT = International Society of Blood Transfusion. See reference 5 for details of the new terminology.
harbouring P. vivax infection, regardless of the presence of a second malaria species, were included in the P. vivax group for this analysis. As expected, no P. vivaxinfected patient was Fy (a-b-), but the prevalence of this phenotype in non-vivax malaria controls (12%) was quite similar to that described in non-Amerindians in Humaitá 2 . Data presented in Table 1 do not support the hypothesis that GATA-1 mutation heterozygosity confers some protection against P. vivax infections 17 , since similar propor tions of homozygotes for the wild-type erythrocyte-specific promoter were found among P. vivax-infected patients (66%) and non-vivax controls (71%) (P = 0.54 by χ 2 analysis). Allele frequencies were remarkably similar in both groups.
The Figure  1 ), was amplified with the primers Fy3 and Fy4, as described elsewhere 12 . PCR mixtures included 1µl of extracted DNA, 0.2µM of each primer, 100µM of each dNTP and 1U of Taq polymerase (Amersham Pharmacia Biotech, USA) in a final reaction volume of 40ml. Mixtures were incubated for 4 min at 94°C, followed by 33 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final incubation at 72°C for 10 min. The C265T mutation was searched for by digesting a 3-µl aliquot of the PCR product with 4U of the restr iction enzyme AciI (New England Biolabs, USA) for 4h at 37°C, since the C265T mutation eliminates an AciI restriction site (CCGC -> CTGC). Restriction fragments were resolved by agarose gel electrophoresis.
No P. ) was heterozygous for the G298A mutation in exon 2; no instances of C265T (or any other) mutation were found. The G298A mutation may also be detected by RFLP analysis with the enzyme MwoI 12 (Figure 1) , and does not seem to affect Fy antigen expression on RBCs 13 . In conclusion, our findings argue against the hypothesis that heterozygosity for the wild-type erythrocyte-specific promoter of the Fy gene, which results in reduced erythrocyte expression of the Duffy antigen 16 17 , may confer some protection against P. vivax infection 17 . No P. vivaxinfected patient was found to bear the Fy x allele. However, since Fy x allele frequencies in local human populations remain undetermined, no conclusion may be drawn from our data regarding the susceptibility to P. vivax infection among individuals with the Fy (a-b+ WK ) phenotype.
